Teleflex Incorporated reports developments for a global medical technology business that supplies hospitals and healthcare providers with devices used in anesthesia, emergency medicine, interventional cardiology and radiology, surgery, vascular access and urology. Its established brands include Arrow, Barrigel, Deknatel, LMA, Pilling, QuikClot, Rüsch, UroLift and Weck.
Recurring Teleflex news covers quarterly financial results, outlook updates, revenue trends by global product category, portfolio realignment and integration of acquired vascular intervention assets. Company updates also include governance and leadership changes, board committee matters, capital allocation actions, shareholder communications and operational initiatives such as integrated demand and supply planning.
Teleflex (NYSE:TFX) announced Board and governance changes on April 9, 2026, including the nomination of Michael J. Tokich as an independent director and the appointment of Andrew A. Krakauer as Chairman effective after the 2026 Annual Meeting.
The Board will form a Growth and Operating Committee to support transformation efforts, and the company plans to commence opportunistic share repurchases under its existing $1 billion authorization beginning in Q2 2026, subject to market conditions and cash flow needs.
Irenic Capital Management, a 2% shareholder in Teleflex (NYSE: TFX), urged the Teleflex board to form a Strategic Review sub-committee with new independent directors, a shareholder representative and exclusion of Dr. Klasko to oversee inbound and outbound strategic processes and report back to shareholders.
Irenic said it disagrees with the board's description of their prior conversation and said it looks forward to working with the board to maximize shareholder value.
Teleflex (NYSE:TFX) reiterated its value-maximizing plan following engagement with activist Irenic on March 19, 2026. The company expects previously announced sale transactions to close in the second half of 2026, yielding approximately $1.8 billion of net proceeds after tax.
Teleflex plans to allocate proceeds to a $1.0 billion share repurchase and $800 million debt paydown, pursue a multi-year restructuring targeting about $50 million annual pre-tax savings by mid-2028, and complete announced divestitures while continuing its CEO search.
Summary not available.
o9 announced that Teleflex (NYSE: TFX) went live globally on o9's platform for integrated Demand Planning and Supply Planning on March 12, 2026.
This deployment connects demand forecasts and supply plans in one environment, improving cross-functional coordination, inventory and capacity visibility, forecast performance, and alignment on trade-offs across regions and functions.
Teleflex (NYSE: TFX) announced a quarterly cash dividend of $0.34 per share. The dividend is payable March 31, 2026 to shareholders of record at the close of business on March 6, 2026.
Shareholders registered by the record date will receive the March 31 payment; more corporate details are available from the company.
Teleflex (NYSE: TFX) reported full-year 2025 continuing operations GAAP revenue of $1,992.7M (+17.2%) and adjusted revenue of $1,983.7M (+16.3%). Adjusted diluted EPS from continuing operations was $6.98.
Management provided 2026 outlook: GAAP revenue growth 14.4%–15.4%, pro forma adjusted constant currency revenue growth 4.5%–5.5%, and adjusted diluted EPS $6.25–$6.55. Company announced strategic divestitures, expected H2 2026 close, estimated $1.8B after-tax proceeds, and an initial restructuring to mitigate $48M–$52M annual stranded costs.
Teleflex (NYSE:TFX) will host a conference call to discuss its fourth quarter 2025 financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, February 26, 2026.
Participation requires pre-registration to receive dial-in details; the call will be available via live audio webcast on the company website and an audio replay will be available beginning at 11:00 a.m. Eastern Time on February 26, 2026 (conference ID 69028).
Teleflex (NYSE: TFX) appointed Stuart Randle as Interim President and CEO effective immediately and named Dr. Stephen Klasko chairman of the board while the Board engages Spencer Stuart to search for a permanent CEO.
The company provided preliminary full‑year 2025 revenue expectations of $3.270 billion to $3.278 billion, revised from prior guidance of $3.305 billion to $3.320 billion. The reduction reflects softer end‑of‑year demand for intra‑aortic balloon pumps and catheters in the U.S. and Asia, delays in certain OEM purchase orders, and lower order volumes across some portfolio segments. Final fourth quarter and full‑year 2025 results are expected in late February/early March 2026.
Teleflex Medical OEM (to be carved out from Teleflex, NYSE: TFX) will be acquired by Montagu and Kohlberg for $1.5 billion. The carve-out creates an independent contract developer and manufacturer serving structural heart, neurovascular, electrophysiology and urology, with seven facilities across the U.S., Mexico and Ireland.
Closing is expected in second half of 2026, subject to customary regulatory approvals and closing conditions. Greg Stotts will become CEO and Matt Jennings will assume the role of Chairman on closing.